Who is sponsoring NCT05374954?

NCT05374954 is sponsored by China National Biotec Group Company Limited.

What drugs are being tested in NCT05374954?

Interventions in NCT05374954: Omicron COVID-19 Vaccine (Vero Cell), Inactivated, COVID-19 Vaccine (Vero Cell), Inactivated.

Is NCT05374954 still recruiting?

NCT05374954 is currently status unknown. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT05374954: COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above

Status unknown Phase 3 Last updated 18 June 2023

What this trial tests

Phase 3 trial testing Omicron COVID-19 Vaccine (Vero Cell), Inactivated in COVID-19 in 4,200 participants. Status unknown.

Timeline

10 May 2022

Primary endpoint
25 September 2022

10 November 2023

Quick facts

Lead sponsor	China National Biotec Group Company Limited
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	4,200
Start date	10 May 2022
Primary completion	25 September 2022
Estimated completion	10 November 2023
Sites	10 locations across China

Drugs / interventions tested

Omicron COVID-19 Vaccine (Vero Cell), Inactivated — full drug profile →
COVID-19 Vaccine (Vero Cell), Inactivated — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

China National Biotec Group Company Limited — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and developments in universal vaccine design against SARS-CoV-2 variants.
Zhao F, Zai X, Zhang Z, Xu J, et al · · 2022 · cited 55× · PMID 36535982 · DOI 10.1038/s41541-022-00597-4
The race for clinical trials on Omicron-based COVID-19 vaccine candidates: Updates from global databases.
Viveiros-Rosa SG, Mendes CD, Farfán-Cano GG, El-Shazly M. · · 2022 · cited 27× · PMID 38449904 · DOI 10.52225/narra.v2i3.88
Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern.
Al-Fattah Yahaya AA, Khalid K, Lim HX, Poh CL. · · 2023 · cited 14× · PMID 36992333 · DOI 10.3390/v15030624

Verify or expand the search:

Other trials of Omicron COVID-19 Vaccine (Vero Cell), Inactivated

Trials testing the same drug.

NCT05365724 — A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 · Phase 1, PHASE2 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other China National Biotec Group Company Limited trials

Trials by the same sponsor.

NCT07338851 — the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines · not yet recruiting
NCT07377175 — Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. · Phase 1 · recruiting
NCT05839301 — A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age · Phase 3 · unknown
NCT05669625 — A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine · Phase 3 · active not recruiting
NCT05480436 — Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05374954 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China National Biotec Group Company Limited
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05374954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing